Bevacizumab for malignant pleural effusion in ovarian clear cell carcinoma: a case report

Objective: Malignant pleural effusion (MPE) is a major problem associated with late phase of epithelial ovarian cancer for which an optimum treatment consensus has yet to be determined. Although bevacizumab (Bev), a VEGF ligand inhibitor, has been shown to effectively control MPE, the clinical benefit of half-dose Bev treatment to control MPE remains unclear. Methods: We describe a patient with platinum-sensitive ovarian clear cell cancer (OCCC) and symptomatic MPE for whom tumor markers increased after one cycle of paclitaxel and carboplatin chemotherapy. After switching to five cycles of Bev plus paclitaxel/carboplatin chemotherapy, we observed the disappearance of MPE. Conclusion: The half-dose Bev therapy may be an effective treatment for MPE in OCCC. However, further investigation is still warranted to evaluate the therapeutic effectiveness of Bev.

VEGF; Ovarian cancer; MPE

[1] Suh DH, Kim HS, Chang S, Bristow RE. Surgical management of recurrent ovarian cancer. Gynecologic Oncology. 2016; 142: 357–367.

[2] Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, et al. The new who classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Archives of Gynecology and Obstetrics. 2016; 293: 695–700.

[3] Kim SI, Lee JW, Lee M, Kim HS, Chung HH, Kim J, et al. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. Gynecologic Oncology. 2018; 148: 375–382.

[4] Paik ES, Lee Y, Shim M, Choi HJ, Kim T, Choi CH, et al. Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2016; 56: 639–647.

[5] Eitan R, Levine DA, Abu-Rustum N, Sonoda Y, Huh JN, Franklin CC, et al. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer. 2005; 103: 1397–1401.

[6] Mironov O, Ishill NM, Mironov S, Vargas HA, Zheng J, Moskowitz CS, et al. Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival. Radiology. 2011; 258: 776–784.

[7] Davies HE, Lee YCG. Management of malignant pleural effusions: questions that need answers. Current Opinion in Pulmonary Medicine. 2013; 19: 374–379.

[8] Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Current Opinion in Pulmonary Medicine. 2002; 8: 294–301.

[9] Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Reviews. 2012; 31: 143–162.

[10] Shimizu Y, Kajiyama H, Yoshida K, Tamauchi S, Nakanishi T, Kikkawa F. The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer. Journal of Obstetrics and Gynaecology Research. 2019; 45: 2435–2439.

[11] Kanzaki R, Inoue M, Kimura T, Kawamura T, Funaki S, Shintani Y, et al. Role of pulmonary metastasectomy in colorectal cancer in the era of modern multidisciplinary therapy. Surgery Today. 2017; 47: 1111–1118.

[12] Mori R, Fujimoto D, Ito M, Tomii K. Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature. Oncotarget. 2017; 8: 48521–48524.

[13] Jia L, DU Y, Li T, Lv Y, Wang Y, Zhang Y, et al. Differential expression of vascular endothelial growth factor-A, -C and -D for the diagnosis and prognosis of cancer patients with malignant effusions. Oncology Letters. 2015; 10: 667–674.

[14] Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. The New England Journal of Medicine. 2011; 365: 2484– 2496.

[15] Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. The New England Journal of Medicine. 2011; 365: 2473–2483.

[16] Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomized trial. The Lancet Oncology. 2015; 16: 928–936.

[17] Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Journal of Clinical Oncology. 2012; 30: 2039–2045.

[18] Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology. 2015; 139: 10–16.